Skip to contentP
Processa Pharmaceuticals, Inc.
P
PCSAProcessa Pharmaceuticals, Inc. Q1 2022 · 10-Q
Revenue$0.00$0.00no prior Q1 2021 on file Net Income-$3.23M-$3.23MN/M vs Q1 2021 EPS, diluted—
Operating Income-$3,228,714N/M Operating Cash Flow-$1,802,926N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Processa Pharmaceuticals, Inc. · CIK 1533743 · Engraved from SEC EDGAR
ended Mar 31, 2022 · filed May 12, 2022 · 42 d after period end